Brickell Biotech (NASDAQ:BBI) Stock Price Down 5.8%

Brickell Biotech, Inc. (NASDAQ:BBIGet Rating) fell 5.8% during trading on Tuesday . The company traded as low as $1.85 and last traded at $1.94. 68,775 shares changed hands during mid-day trading, a decline of 67% from the average session volume of 206,730 shares. The stock had previously closed at $2.06.

Brickell Biotech Price Performance

The firm has a 50-day moving average of $2.93 and a 200 day moving average of $6.93. The company has a market capitalization of $5.58 million, a PE ratio of -0.14 and a beta of 0.02.

Brickell Biotech (NASDAQ:BBIGet Rating) last released its earnings results on Thursday, August 11th. The company reported ($0.01) EPS for the quarter, topping the consensus estimate of ($1.48) by $1.47. Brickell Biotech had a negative net margin of 643.48% and a negative return on equity of 156.10%. During the same period in the prior year, the firm earned ($7.21) EPS. Equities analysts expect that Brickell Biotech, Inc. will post -7.66 EPS for the current year.

Hedge Funds Weigh In On Brickell Biotech

An institutional investor recently raised its position in Brickell Biotech stock. Vanguard Group Inc. grew its stake in Brickell Biotech, Inc. (NASDAQ:BBIGet Rating) by 14.8% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 3,112,092 shares of the company’s stock after acquiring an additional 401,276 shares during the quarter. Vanguard Group Inc. owned about 2.61% of Brickell Biotech worth $832,000 as of its most recent SEC filing.

Brickell Biotech Company Profile

(Get Rating)

Brickell Biotech, Inc, a clinical-stage pharmaceutical company, engages in the development of various prescription therapeutics for the treatment of autoimmune, inflammatory, and other debilitating diseases in the United States. The company develops sofpironium bromide, which has completed Phase III clinical trials for the treatment of primary axillary hyperhidrosis; BBI-02, an oral DYRK1A inhibitor for the treatment of autoimmune and inflammatory diseases; and BBI-10, a covalent stimulator of interferon genes inhibitor for the potential treatment of autoinflammatory and rare genetic diseases, as well as next-generation kinase inhibitors.

Further Reading

Receive News & Ratings for Brickell Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Brickell Biotech and related companies with MarketBeat.com's FREE daily email newsletter.